Accro Bioscience to Present Phase II Results of Oral TYK2/JAK1 Inhibitor AC-201 in Psoriasis at EADV 2025

Accro Bioscience to Present Phase II Results of Oral TYK2/JAK1 Inhibitor AC-201 in Psoriasis at EADV 2025

By, Admin 5 September 2025

Accro Bioscience (Accropeutics), a clinical-stage biotech focused on regulated cell death and related disease pathways, will present Phase II clinical results of AC-201 in moderate-to-severe plaque psoriasis at the European Academy of Dermatology & Venereology (EADV) Congress, September 17–20, Paris.

Presentation Details

  • Abstract Type: Oral Presentation (Late Breaking Session)
  • Abstract ID: LBA-5
  • Title: Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial
  • Session: D3T01.4F
  • Room: Paris Nord
  • Time: Friday, September 19 | 17:15 – 17:30

About AC-201

  • Mechanism: A highly selective, potent oral small-molecule inhibitor of TYK2/JAK1, binding the pseudokinase domain (JH2) with minimal effect on JAK2/JAK2 signaling.
  • Indications under development:
    - Psoriasis (PsO)
    - Non-infectious uveitis (NIU)
    - Cutaneous lupus erythematosus (CLE)
  • Safety profile: Phase 1 trials in Australia and China showed AC-201 was safe, well tolerated, with no discontinuations or serious adverse events.
  • Phase 2 (Psoriasis): Completed with positive efficacy and safety outcomes, supporting advancement to later-stage trials.

About Accro Bioscience

  • Focus: Targeting regulated cell death and immune-mediated pathogenesis.
  • Clinical pipeline:
    - AC-201: Selective TYK2/JAK1 inhibitor; Phase 2 in PsO complete.
    - AC-101: RIPK2 inhibitor; Ph1 completed (Australia/China), Ph1b ongoing in ulcerative colitis.
    - AC-003: RIPK1 inhibitor; FDA Orphan Drug Designation for aGvHD; Ph1 complete in US/China; Ph1b ongoing in aGvHD.
  • Global rights: Owns worldwide IP with 25 patents issued across China, Japan, US, Korea, EU.

Why It Matters

  • TYK2/JAK pathway inhibition is emerging as a transformative approach in immune-mediated inflammatory diseases.
  • AC-201 offers the potential for a selective, oral treatment with fewer off-target effects than traditional JAK inhibitors.
  • The EADV presentation could position Accro as a competitive player alongside Bristol Myers Squibb’s deucravacitinib and other next-generation TYK2 programs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!